Case report: A case of neoadjuvant immunotherapy in combination with the Yang–Monti technique for the treatment of ureteral carcinoma after radical cystectomy and left radical nephroureterectomy

Tielin Wu, Harris Haleem and Min Yin*
Department of Urology, Ningbo Medical Treatment Centre Li Huili Hospital, Ningbo, China

Recurrence of urothelial carcinoma in a patient with solitary kidney is always a clinical challenge. In the immune checkpoint inhibitor era, neoadjuvant immunotherapy in combination with the Yang–Monti technique might be a good option for the patient with a high-risk tumor when kidney-sparing surgery for renal function preservation is desired. We report the case of a 74-year-old man with solitary kidney who was diagnosed with recurrence of urothelial carcinoma in the right ureter. He was initially deemed unfit for segmental resection of the ureter. Neoadjuvant immunotherapy with tislelizumab was performed in this patient with a partial response to urothelial carcinoma. He underwent segmental resection of the ureter with negative margins, and the ureteral defect was bridged by modified ileal replacement, which is the Yang–Monti technique. This patient has remained disease-free with adequate kidney function for longer than 18 months.

KEYWORDS
neoadjuvant immunotherapy, tislelizumab, Yang-Monti technique, solitary kidney, Recurrence of urothelial carcinoma, anti-programmed death protein-1

Background

The upper urinary tract is the most common site of late recurrence following bladder cancer (1). Recurrence of urothelial carcinoma in a patient with solitary kidney is always a clinical challenge. In low-risk cancers, kidney-sparing surgery (KSS) is the preferred approach as survival is similar to that after radical nephroureterectomy (RNU), which
includes removing the kidney, ureter, and partially the bladder (2). However, it is still unknown what is the best choice for high-risk tumors when KSS for renal function preservation is desired. Seisen showed that there was no difference in cancer-specific survival or other oncologic outcomes between KSS and RNU; thus, segmental ureterectomy could also be used in a select subset of high-grade and invasive UTUC (2). The guidelines recommend case-dependent consideration of biopsy grade, imaging findings, and urine cytology when deciding between RNU and KSS (1). After segmental ureterectomy, long ureteral defects remained a challenge to urologists. Many techniques, such as ileal ureter, appendiceal interposition, and reconfigured colon substitution, have been described in literature to reconstruct the long defect of ureter rather than direct re-anastomosis. The Yang–Monti principle, which was firstly described by Yang in 1993 and was verified by Monti et al., allows the creation of a long tube from a short bowel segment after its reconfiguration (3, 4).

Neoadjuvant platinum-based chemotherapy represents the standard treatment for non-metastatic muscle invasive bladder cancer (MIBC) (5). However, there are cisplatin-ineligible patients, who could not benefit from chemotherapy before surgery. PURE-01 was a neoadjuvant immunotherapy trial for bladder cancer, which had shown a pathological complete response (pT0) rate of 42%, and pT0 was associated with high tumor mutational burden (TMB) and DNA damage response (DDR) gene alterations (6). Despite the good outcomes in MIBC, neoadjuvant therapy in UTUC does not yield level I evidence as there are only several retrospective studies published thus far. Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, demonstrated meaningful clinical benefits in patients with previously treated locally advanced urothelial carcinoma and had a manageable safety profile (7). We report a case of recurrence of urothelial carcinoma with DDR gene alterations and high TMB, which got a partial response to neoadjuvant immunotherapy with tislelizumab. After neoadjuvant immunotherapy, segmental ureterectomy was performed and a long ureteral defect was bridged with the Yang–Monti technique.

Case presentation

This case report was approved by the research ethics committee of Ningbo Medical Treatment Centre Li Huiili Hospital (Ethical Approval Number: QT2020P050). A 74-year-old man who had a history of radical cystectomy and left radical nephroureterectomy due to MIBC and left renal pelvis carcinoma was diagnosed with recurrent urothelial carcinoma in the right ureter. In 2012, this patient was diagnosed with MIBC and received laparoscopic radical cystectomy + pelvic lymph node dissection (PLND) accompanied by orthotopic neobladder reconstruction with ileal conduit, pathologically staged as T2N0M0. The postoperative pathology was high-grade invasive urothelial carcinoma that was partly micropapillary and showed infiltration into the lamina propria; no metastasis was seen in 17 retrieved lymph nodes. He was treated with adjuvant cisplatin-containing combination chemotherapy for four courses. Patient follow-up was performed from 2012 to 2018 with abdominal-pelvis computed tomography (CT) (Figure 1A). In 2019, 7 years after radical cystectomy, he showed macrohematuria. CT showed morphological changes in the left renal pelvis without a ureteral lesion present (Figure 1B), and cancer cells were found in urine cytology. Radical nephroureterectomy was performed in April 2019. The left kidney and ureter along with a part of bladder were removed. The pathological result identified high-grade urothelial papillary carcinoma of the left renal pelvis, with a mass size of 3 cm * 2 cm *1 cm, infiltrating the fat of the renal sinus and close to the renal parenchyma, involving the proximal ureter, with visible choroidal carcinoma thrombus. The lesion was indicated as locally advanced urothelial carcinoma with a stage of T3N0M0 (Figure 1C).

After 1 year of regular follow-up, CT revealed recurrence of the right ureteral carcinoma with obstructive hydrenephrosis, cT3N0M0 (Figure 1D). The calculated eGFR was 37.157 ml/min/1.73 m²; considering the risk of renal failure due to cisplatin, the patient was treated with tislelizumab (200 mg ivgtt q3w) for three courses. Nine weeks later, CT revealed that the maximum diameter of the tumor shrunk from 25 to 15 mm, suggesting a partial response (PR) to tislelizumab (Figure 1E). This patient had a strong desire to preserve his kidney and refused to receive a right ureteronephrectomy associated with hemodialysis. Therefore, he was treated with partial right ureteral resection (including part of the input collaterals of the original Studer bladder) + modified ileal replacement for ureteral defect, which is the Yang–Monti technique. Firstly, the right ureteral tumor was removed and then a section of approximately 12 cm of ileum was isolated on its mesenteric branch. The isolated ileal segment is then divided into three ileal pieces accompanying mesenteric blood supply. These rings are opened with an incision at the paramesenteric border. These three strips are joined at the ends, to make a rectangular piece of 18 cm in length, which is then tubularized around a single "J" stent to form a tube of suitable length (Figures 2A-E). The operation went well, and the postoperative pathology was invasive high-grade urothelial carcinoma, with infiltration into the muscular layer of the canal wall and negative margins on both sides (Figure 2F). Five days after the operation, the patient began to develop psychiatric symptoms such as prosopagnosia. We speculated that the psychiatric symptoms might be caused by postoperative stress; thus, the patient received sedation and oral symptomatic treatment with risperidone. The status of the patient gradually improved and he was discharged in about 10 days. After discharge, he received continuous tislelizumab treatment. After 2 months of follow-up, his calculated eGFR was 53.71 ml/min/1.73 m², indicating the recovery of renal function. RNA sequencing with DDR gene alterations showed a possible beneficial role of platinum-based...
chemotherapy. The patient completed four courses of GC chemotherapy in combination with tislelizumab immunotherapy. He is still on tislelizumab immunotherapy at 18 months of follow-up, and no recurrence or distant metastases were observed (Figure 2G). The treatment flowchart is shown in Figure 3.

Discussion

We describe a patient who initially presented with recurrence of urothelial carcinoma in the ureter after radical cystectomy and left radical nephroureterectomy. He was started on neoadjuvant
immunotherapy with tislelizumab and had a partial pathologic response within the tumor. Tislelizumab was well-tolerated and resulted in vast improvement in performance status, which permitted consolidative surgical therapy with curative intent. As one type of ICIs, tislelizumab has been used to treat urothelial carcinoma. In our case, after three courses, tislelizumab shrunk the tumor in both extension and diameter, down staging clinically from cT3 to cT2. To investigate why this patient had such a good response to tislelizumab, RNA sequencing was tested, which suggested high TMB (31.84 Muts/Mb) and DDR gene alterations. High TMB and DDR gene alterations may suggest a good response to ICIs (6). Meanwhile, Min Yuen Teo showed that defects in DDR genes have a significant impact on sensitivity to platinum therapy (8). The POUT trial was a phase 3, open-label, randomized controlled trial, which had shown gemcitabine–platinum combination chemotherapy initiated within 90 days after nephroureterectomy significantly improved disease-free survival in patients with locally advanced UTUC (9).

To our knowledge, this is the first reported case of recurrence of urothelial carcinoma after radical cystectomy and left radical nephroureterectomy treated with neoadjuvant immunotherapy in combination with segmental ureterectomy, which was reconstructed by the Yang–Monti technique. This patient has a past history of MIBC 7 years ago, and has a recurrence of urothelial carcinoma in his right ureter less than 1 year after his treatment of left renal pelvis cancer. Meanwhile, CT showed that the tumor had invaded the fat around the ureter, suggesting a clinical stage cT3, which means that if this patient had a strong desire to preserve his kidney, neoadjuvant therapy was needed. However, the calculated eGFR was 37.157 ml/min/1.73 m², and considering the high risk of renal failure due to cisplatin, neoadjuvant immunotherapy was worth trying. Fortunately, the tumor had a good response to tislelizumab, which made segmental ureterectomy plus the Yang–Monti technique a better option.

As shown by some investigators, the Yang–Monti technique is effective and has numerous advantages over both intact and tapering ileal ureters. It allows the reconfiguration of short ileal segments into long tubes of small caliber by converting the circular fibers into longitudinal ones (10). An ileal segment can replace approximately threefold length of ureteral defects after reconfiguration, and its diameter is close to that of the ureter. Yang–Monti ileal ureters mimic the function of a native ureter, providing active antegrade propulsion for urinary drainage (11). The possibility of excessive mucus production and metabolic acidosis is almost absent because of the reduction of surface area with secretive and absorptive characteristics (10). A nonconcurrent cohort study, in which Yang–Monti ileal ureter reconstruction was performed in 36 patients between 2001 and 2019, shows that the Yang–Monti ileal ureter is durable and effective in improving kidney function with few complications. It can be safely used in cases of mild/moderate kidney function loss and solitary kidney (12). Thus, because of these excellent results, the Yang–Monti technique gained wider recognition and acceptance.

There are some limitations to this analysis. Primarily, there are currently no approved neoadjuvant systemic treatments for patients with UTUC. Although, in our case, the urothelial carcinoma had a response to neoadjuvant immunotherapy, more cases still need to be explored to determine whether neoadjuvant immunotherapy could improve the OS. Secondly, the follow-up time is only 18 months; thus, we do not know whether the urothelial carcinoma is really curable.

**Conclusion**

Preoperative immunotherapy with tislelizumab for locally advanced ureteral carcinoma accompanied by solitary kidney resulted in a partial response, which enabled curative intent and segmental resection of ureter. The Yang–Monti technique is an efficient way to correct clinical ureteral defects after segmental ureterectomy.

**Data availability statement**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
Ethics statement

The studies involving human participants were reviewed and approved by The Research Ethics Committee of Ningbo Medical Treatment Centre Li Huili Hospital. The patients/participants provided their written informed consent to participate in this study.

Author contributions

TW and HH drafted the manuscript. MY did the surgery. All authors read and approved the final manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. *Eur Urol* (2012) 62(2):290–302. doi:10.1016/j.eururo.2012.05.008

2. Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. *Eur Urol* (2016) 70(6):1052–68. doi:10.1016/j.eururo.2016.07.014

3. Monti PR, Lara RC, Dutra MA, de Carvalho JR. New techniques for construction of efferent conduits based on the mitrofanoff principle. *Urology* (1997) 49(1):112–5. doi:10.1016/S0090-4295(96)00503-1

4. Yang WH. Yang needle tunneling technique in creating antireflux and continent mechanisms. *J Urol* (1993) 150(3):830–4. doi:10.1016/S0022-5347(17)5625-2

5. Witjes JA, Max Bruins HI, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. *European urology* (2021) 79(1):82-104 doi:10.1016/j.euro.2020.03.055

6. Necchi A, Anichini A, Raggi D, Brigantti A, Massa S, Luciano R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01). An open-label, single-arm, phase II study. *J Clin Oncol* (2018) 36(34):3353–60. doi:10.1200/JCO.18.01148

7. Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. *Cancer Sci* (2021) 112(1):305–13. doi:10.1111/cas.14681

8. Teo MY, Bambury RM, Zahor EC, Jordan E, Al-Ahmadi H, Boyd ME, et al. DNA Damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. *Clin Cancer Res* (2017) 23(14):3610–8. doi:10.1158/1078-0432.CCR-16-2520

9. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. *Lancet* (2020) 395(10232):1268–77. doi:10.1016/S0140-6736(20)30415-3

10. Xiong S, Zhu W, Li X, Zhang P, Wang H, Li X. Intestinal interposition for complex ureteral reconstruction: A comprehensive review. *Int J Urol* (2020) 27(5):377–86. doi:10.1111/iju.14222

11. Maigaard T, Kirkeby HJ. Yang-monti ileal ureter reconstruction. *Scand J Urol* (2015) 49(4):313–8. doi:10.3109/21681805.2014.882980

12. Al-EI-Dein R, El-Hefnawy AS, D’Elia G, El-Mekresh MM, Shokeir AA, Gad H, et al. Long-term outcome of yang-monti ileal replacement of the ureter: A technique suitable for mild, moderate loss of kidney function and solitary kidney. *Urology* (2021) 152:153–9. doi:10.1016/j.urology.2020.09.061